ATOP Trial: Adjuvant Ado-Trastuzumab Emtansine (T-DMI) for Older Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer (DF/HCC 18-124)

Study Details

This research study is studying an investigational drug as a possible treatment for breast cancer that is positive for the protein Human Epidermal Growth Factor Receptor 2, also known as HER2-positive breast cancer.

Learn More

ClinicalTrials.gov NCT number
NCT03587740

Principal Investigators

  • Steve Lo, MD
Sponsor(s)
Dana-Farber Cancer Institute
Contact
Mary Miller, LPN at 203-358-8879
or officeofresearch@stamhealth.org

Location

  • Bennett Cancer Center
    One Hospital Plaza
    Stamford, CT 06902
    Main: 203-276-2695